Steiner Markus J, Kwok Cynthia, Dominik Rosalie, Byamugisha Josaphat K, Chipato Tsungai, Magwali Thulani, Mmiro Francis, Rugpao Sungwal, Sriplienchan Somchai, Morrison Charles S
Family Health International, Research Triangle Park, North Carolina 27709, USA.
Obstet Gynecol. 2007 Nov;110(5):1003-9. doi: 10.1097/01.AOG.0000268804.98744.2b.
To estimate the probability of pregnancy for oral contraceptive pill (OCP), injectable contraceptive, and condom users in Uganda, Thailand, and Zimbabwe.
This study is a secondary analysis of 5,224 women who participated in a prospective study evaluating the association between hormonal contraception and human immunodeficiency virus (HIV) acquisition.
The overall 12-month cumulative probability of pregnancy of injectable contraceptive users was 0.6% (95% confidence interval [CI] 0.3-1.0), with similar risks in Uganda (0.3%, 95% CI 0-0.7), Thailand (0.6%, 95% CI 0-1.2), and Zimbabwe (1.0%, 95% CI 0.3-1.7). The 12-month cumulative probability of pregnancy for OCP users was 9.5% (95% CI 8.1-11.0%), with similar risks of pregnancy in Uganda and Zimbabwe (14.6%, 95% CI 11.7-17.4; and 10.2%, 95% CI 8.0-12.5, respectively) but substantially lower risk in Thailand (0.5%, 95% CI 0-1.2). The overall 12-month cumulative probability of pregnancy for women intending to use a given method at baseline was 2.0% (95% CI 1.4-2.6%) for injectable contraceptives, 15.7% (95% CI 14.1-17.3%) for OCPs, and 25.8% (95% CI 23.2-28.4) for condoms. Women in Thailand experienced lower pregnancy risk with condoms (18.4%, 95% CI 11.1-25.7) than in Uganda (29.5%, 95% CI 25.7-33.4), and Zimbabwe (23.3%, 95% CI 19.4-27.2).
The overall risk of pregnancy for injectable contraceptive users was substantially lower than for oral contraceptive pill users. However, Thai participants had similarly low cumulative pregnancy probabilities for both methods. Women receiving contraceptive counseling should be informed that their experience with a given method may differ from the average or typical-use pregnancy rates often discussed during contraceptive counseling. Tailored counseling is necessary for women to make informed choices.
II.
评估乌干达、泰国和津巴布韦口服避孕药(OCP)、注射用避孕药及避孕套使用者的怀孕概率。
本研究是对5224名参与前瞻性研究的女性进行的二次分析,该前瞻性研究评估了激素避孕与人类免疫缺陷病毒(HIV)感染之间的关联。
注射用避孕药使用者的12个月累计怀孕概率为0.6%(95%置信区间[CI]0.3 - 1.0),在乌干达(0.3%,95%CI 0 - 0.7)、泰国(0.6%,95%CI 0 - 1.2)和津巴布韦(1.0%,95%CI 0.3 - 1.7)风险相似。OCP使用者的12个月累计怀孕概率为9.5%(95%CI 8.1 - 11.0%),在乌干达和津巴布韦怀孕风险相似(分别为14.6%,95%CI 11.7 - 17.4;10.2%,95%CI 8.0 - 12.5),但在泰国风险显著较低(0.5%,95%CI 0 - 1.2)。基线时打算使用特定方法的女性,注射用避孕药的12个月累计怀孕概率为2.0%(95%CI 1.4 - 2.6%),OCP为15.7%(95%CI 14.1 - 17.3%),避孕套为25.8%(95%CI 23.2 - 28.4)。泰国女性使用避孕套的怀孕风险(18.4%,95%CI 11.1 - 25.7)低于乌干达(29.5%,95%CI 25.7 - 33.4)和津巴布韦(23.3%,95%CI 19.4 - 27.2)。
注射用避孕药使用者的总体怀孕风险显著低于口服避孕药使用者。然而,泰国参与者使用这两种方法的累计怀孕概率同样较低。接受避孕咨询的女性应被告知,她们使用特定方法的体验可能与避孕咨询中经常讨论的平均或典型使用怀孕率不同。为使女性做出明智选择,提供个性化咨询很有必要。
II级